Lilly budgets $1.8B to boost Kisunla, GLP-1 manufacturing in Ireland

Anna Brown

News Reporter

Eli Lilly is rapidly increasing its presence in Ireland with a $1 billion expansion to bolster its biologic drug production and a separate $800 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly budgets $1.8B to boost Kisunla, GLP-1 manufacturing in Ireland

Anna Brown

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Bad trip: How culture conflict and a need for cash nearly broke Lykos

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Cigna sues FTC, calling for withdrawal of 'biased, erroneous' PBM report

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers

Breaking down silos with a new quantitative approach to drug development

Lil­ly bud­gets $1.8B to boost Kisun­la, GLP-1 man­u­fac­tur­ing in Ire­land

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Lilly budgets $1.8B to boost Kisunla, GLP-1 manufacturing in Ireland